Thursday, December 23, 2010 2:56:57 PM
On Dec 23, 2010, at 11:21 AM
Dear Dr. Seymour I just wanted to take a moment to wish you and your family a very Merry Christmas and to thank you for all the time and effort you put into NNVC each and every day of your life. NNVC is going to be a life changer for us all and it keeps me soooooooooooooo EXCITED !!!!!!!!!!! Something else that has me VERY excited is that NNVC has been invited to present at the Dengue Research meeting sponsored by the National Institutes Of Health. I would love to be there because I'm feeling something HUGE could be announced since Dr. Eva Harris of UC Berkeley and Dr. Harold Margolis Chief Of Dengue Branch Of CDC are attending !!!!!!!!! Well February is just around the corner and I CAN'T WAIT !!!!!!!
Take care,
Sincerely,
Patricia
Certainly OK to share
All of this is public information
Dear Patricia,
Thanks for the kind wishes.
I'm very excited about the prospects for the Company in 2011.
We've gained a reputation in the scientific community for doing innovative work in viral therapeutics.
Everything we're now doing is focused on document preparation for the FDA filings. That includes lots of laboratory and animal data on our various lead candidates.
Some have complained that we're moving too slowly.
I think that for a 5 year old company to have 9 drugs in the pipeline with 5 lead candidates for sequencing into the FDA and having done this for around $17M +/- is nothing short of amazing. And each of those candidates addresses a $1B+ market! We're actively seeking analytic and pharmaceutical chemists. I'm amazed that so many of those people feel more comfortable working for a large company where layoffs happen all the time rather than a rapid growth entrepreneurial company with some amazing technology. More people would enable us to move faster although we're still constrained by the available time in the University and government animal labs!
That being said, 2011 should be a terrific year
Sincerely,
EUGENE SEYMOUR, MD, MPH
Chief Executive Officer
NANOVIRICIDES, INC
Nanotechnology-based targeted anti-viral therapeutics
http://www.nanoviricides.com
eugene@nanoviricides.com
310-486-5677
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM